TABLES OF RULES 2002

PROTEASE INHIBITORS

Nucleoside and Nucleotide reserve transcriptase inhibitors Protease inhibitors

Non-Nucleoside reserve transcriptase inhibitors

  Mutations associated to resistance Mutations associated to « possible resistance »
IDV
M46I/L
V82A/F/S/T
I84V
L90M and at least 2 among : K20M/R, L24I, V32I, M36I, I54V/L/M/T, A71V/T, G73S/A, V77I
L90M
SQV
G48V
I84V
L90M
V82A/F/S/T and at least 2 among: I54V/L/M/T, A71V/T, G73S, V77I
NFV
D30N
I84V
N88S/D
L90M
V82A/F/S/T and at least 2 among: L10I, M36I, M46I/L, I54V/L/M/T, A71V/T, V77I
RTV
M46I/L
V82A/F/S/T
I84V
L90M and at least 2 among: K20M/R, L24I, V32I, M36I, I54V/L/M/T, A71V/T, G73S/A, V77I
L90M
APV
I50V
At least 4 mutations among : L10I, V32I, M46I/L, I47V, I54L/M/V, G73S, V82A/F/I/T/S, I84V, L90M
 
APV/RTV
I50V
At least 6 mutations among : L10I, V32I, M46I/L, I47V, I54L/M/V, G73S, V82A/F/I/T/S, I84V, L90M
 
LPV/r
At least 8 mutations among : L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V, L90M
6 or 7 mutations among: L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V, L90M
ATV I50L : no enough data to provide any recommendation in Protease inhibitors experienced patients V32I and M46I and I84V and N88S

IDV: indinavir, SQV: saquinavir, NFV: nelfinavir, RTV: ritonavir, APV: amprenavir, LPV: lopinavir, ATV:atazanavir